Switch theme
Sign up to access all valuation multiples
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
2015
188
LTM Revenue $55.0M
LTM EBITDA -$277M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kymera Therapeutics has a last 12-month revenue (LTM) of $55.0M and a last 12-month EBITDA of -$277M.
In the most recent fiscal year, Kymera Therapeutics achieved revenue of $47.1M and an EBITDA of -$216M.
Kymera Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kymera Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $55.0M | XXX | $47.1M | XXX | XXX | XXX |
| Gross Profit | $55.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$277M | XXX | -$216M | XXX | XXX | XXX |
| EBITDA Margin | -504% | XXX | -459% | XXX | XXX | XXX |
| EBIT | -$286M | XXX | -$257M | XXX | XXX | XXX |
| EBIT Margin | -521% | XXX | -545% | XXX | XXX | XXX |
| Net Profit | -$252M | XXX | -$224M | XXX | XXX | XXX |
| Net Margin | -459% | XXX | -476% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kymera Therapeutics's stock price is $30.
Kymera Therapeutics has current market cap of $1.9B, and EV of $1.6B.
See Kymera Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.9B | XXX | XXX | XXX | XXX | $-3.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kymera Therapeutics has market cap of $1.9B and EV of $1.6B.
Kymera Therapeutics's trades at 33.0x EV/Revenue multiple, and -7.2x EV/EBITDA.
Equity research analysts estimate Kymera Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kymera Therapeutics has a P/E ratio of -7.7x.
See valuation multiples for Kymera Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 28.3x | XXX | 33.0x | XXX | XXX | XXX |
| EV/EBITDA | -5.6x | XXX | -7.2x | XXX | XXX | XXX |
| EV/EBIT | -5.4x | XXX | -6.1x | XXX | XXX | XXX |
| EV/Gross Profit | 28.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -8.6x | XXX | XXX | XXX |
| EV/FCF | -8.2x | XXX | -7.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKymera Therapeutics's last 12 month revenue growth is 30%
Kymera Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.6M for the same period.
Kymera Therapeutics's rule of 40 is -152% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kymera Therapeutics's rule of X is -429% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kymera Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Margin | -504% | XXX | -459% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -152% | XXX | -429% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -429% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 510% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 645% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kymera Therapeutics acquired XXX companies to date.
Last acquisition by Kymera Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Kymera Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kymera Therapeutics founded? | Kymera Therapeutics was founded in 2015. |
| Where is Kymera Therapeutics headquartered? | Kymera Therapeutics is headquartered in United States of America. |
| How many employees does Kymera Therapeutics have? | As of today, Kymera Therapeutics has 188 employees. |
| Who is the CEO of Kymera Therapeutics? | Kymera Therapeutics's CEO is Dr. Nello Mainolfi, PhD. |
| Is Kymera Therapeutics publicy listed? | Yes, Kymera Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Kymera Therapeutics? | Kymera Therapeutics trades under KYMR ticker. |
| When did Kymera Therapeutics go public? | Kymera Therapeutics went public in 2020. |
| Who are competitors of Kymera Therapeutics? | Similar companies to Kymera Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kymera Therapeutics? | Kymera Therapeutics's current market cap is $1.9B |
| What is the current revenue of Kymera Therapeutics? | Kymera Therapeutics's last 12 months revenue is $55.0M. |
| What is the current revenue growth of Kymera Therapeutics? | Kymera Therapeutics revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Kymera Therapeutics? | Current revenue multiple of Kymera Therapeutics is 28.3x. |
| Is Kymera Therapeutics profitable? | Yes, Kymera Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kymera Therapeutics? | Kymera Therapeutics's last 12 months EBITDA is -$277M. |
| What is Kymera Therapeutics's EBITDA margin? | Kymera Therapeutics's last 12 months EBITDA margin is -504%. |
| What is the current EV/EBITDA multiple of Kymera Therapeutics? | Current EBITDA multiple of Kymera Therapeutics is -5.6x. |
| What is the current FCF of Kymera Therapeutics? | Kymera Therapeutics's last 12 months FCF is -$190M. |
| What is Kymera Therapeutics's FCF margin? | Kymera Therapeutics's last 12 months FCF margin is -346%. |
| What is the current EV/FCF multiple of Kymera Therapeutics? | Current FCF multiple of Kymera Therapeutics is -8.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
